Kala Pharmaceuticals Inc
NASDAQ:KALA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kala Pharmaceuticals Inc
Other Current Assets
Kala Pharmaceuticals Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kala Pharmaceuticals Inc
NASDAQ:KALA
|
Other Current Assets
$3.2m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Assets
$4.2B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Assets
$1.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
6%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Assets
$2.8B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Assets
$9.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Assets
$14.5B
|
CAGR 3-Years
70%
|
CAGR 5-Years
38%
|
CAGR 10-Years
37%
|
|
Kala Pharmaceuticals Inc
Glance View
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 192 full-time employees. The company went IPO on 2017-07-20. The firm's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS product is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS product is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The firm's AMPPLIFY technology uses selectively-sized nanoparticles that each have a coating. The firm also has a pipeline of development programs, including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCED) and multiple new chemical entity (NCE) preclinical development programs targeted to address unmet medical needs.
See Also
What is Kala Pharmaceuticals Inc's Other Current Assets?
Other Current Assets
3.2m
USD
Based on the financial report for Sep 30, 2025, Kala Pharmaceuticals Inc's Other Current Assets amounts to 3.2m USD.
What is Kala Pharmaceuticals Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
-5%
Over the last year, the Other Current Assets growth was 53%. The average annual Other Current Assets growth rates for Kala Pharmaceuticals Inc have been -54% over the past three years , -5% over the past five years .
